Lu, C., Kang, T., Zhang, J., Yang, K., Liu, Y., Song, K., Lin, Q., Dixit, D., Gimple, R. C., Zhang, Q., Shi, Z., Fan, X., Wu, Q., Li, D., Shan, D., Gao, J., Gu, D., You, H., Li, Y., … Wang, X. (2025). Combined targeting of glioblastoma stem cells of different cellular states disrupts malignant progression. Nature Communications, 16(1). https://doi.org/10.1038/s41467-025-58366-5

Haile, H., Upadhyayula, P. S., Karlovich, E., Sisti, M. B., Gill, B. J. A., & Donovan, L. E. (2025). Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report. Acta Neuropathologica Communications, 13(1). https://doi.org/10.1186/s40478-024-01894-w

Gao, J., Gu, D., Yang, K., Zhang, J., Lin, Q., Yuan, W., Zhu, X., Dixit, D., Gimple, R. C., You, H., Zhang, Q., Shi, Z., Fan, X., Wu, Q., Lu, C., Cheng, Z., Li, D., Zhao, L., Xue, B., … Wang, X. (2025). Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding. Cancer Cell, 43(1), 122-143.e8. https://doi.org/10.1016/j.ccell.2024.12.006

Lv, D., Dixit, D., Cruz, A. F., Kim, L. J. Y., Duan, L., Xu, X., Wu, Q., Zhong, C., Lu, C., Gersey, Z. C., Gimple, R. C., Xie, Q., Yang, K., Liu, X., Fang, X., Wu, X., Kidwell, R. L., Wang, X., Bao, S., … Rich, J. N. (2024). Metabolic regulation of the glioblastoma stem cell epitranscriptome by malate dehydrogenase 2. Cell Metabolism, 36(11), 2419-2436.e8. https://doi.org/10.1016/j.cmet.2024.09.014

Latzer, P., Zelba, H., Battke, F., Reinhardt, A., Shao, B., Bartsch, O., Rabsteyn, A., Harter, J., Schulze, M., Okech, T., Golf, A., Kyzirakos-Feger, C., Kayser, S., Pieper, N., Feldhahn, M., Wünsche, J., Seitz, C., Hadaschik, D., Garbe, C., … Biskup, S. (2024). A real-world observation of patients with glioblastoma treated with a personalized peptide vaccine. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-51315-8

Nguyen, T. T. T., Gao, Q., Mun, J.-Y., Zhu, Z., Shu, C., Naim, A., Rogava, M., Izar, B., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. (2024). Suppressing PD-L1 Expression via AURKA Kinase Inhibition Enhances Natural Killer Cell-Mediated Cytotoxicity against Glioblastoma. Cells, 13(13), 1155. https://doi.org/10.3390/cells13131155

Cheng, Y. L., Banu, M. A., Zhao, W., Rosenfeld, S. S., Canoll, P., & Sims, P. A. (2024). Multiplexed single-cell lineage tracing of mitotic kinesin inhibitor resistance in glioblastoma. Cell Reports, 43(5), 114139. https://doi.org/10.1016/j.celrep.2024.114139

Li, D., Wang, X., Chen, K., Shan, D., Cui, G., Yuan, W., Lin, Q., Gimple, R. C., Dixit, D., Lu, C., Gu, D., You, H., Gao, J., Li, Y., Kang, T., Yang, J., Yu, H., Song, K., Shi, Z., … Wang, X. (2024). IFI35 regulates non-canonical NF-κB signaling to maintain glioblastoma stem cells and recruit tumor-associated macrophages. Cell Death & Differentiation, 31(6), 738–752. https://doi.org/10.1038/s41418-024-01292-8

Wang, L., Wang, H., D’Angelo, F., Curtin, L., Sereduk, C. P., Leon, G. D., Singleton, K. W., Urcuyo, J., Hawkins-Daarud, A., Jackson, P. R., Krishna, C., Zimmerman, R. S., Patra, D. P., Bendok, B. R., Smith, K. A., Nakaji, P., Donev, K., Baxter, L. C., Mrugała, M. M., … Li, J. (2024). Quantifying intra-tumoral genetic heterogeneity of glioblastoma toward precision medicine using MRI and a data-inclusive machine learning algorithm. PLOS ONE, 19(4), e0299267. https://doi.org/10.1371/journal.pone.0299267

Liu, Z., Mela, A., Argenziano, M. G., Banu, M. A., Furnari, J., Kotidis, C., Sperring, C. P., Humala, N., Mahajan, A., Bruce, J. N., Canoll, P., & Sims, P. A. (2024). Single-cell analysis of 5-aminolevulinic acid intraoperative labeling specificity for glioblastoma. Journal of Neurosurgery, 140(4), 968–978. https://doi.org/10.3171/2023.7.jns23122

IGNATOVA, T. N., CHAITIN, H. J., KUKEKOV, N. V., SUSLOV, O. N., DULATOVA, G. I., HANAFY, K. A., & VRIONIS, F. D. (2024). Gliomagenesis is orchestrated by the Oct3/4 regulatory network. Journal of Neurosurgical Sciences, 68(2). https://doi.org/10.23736/s0390-5616.21.05437-0

Nguyen, T. T. T., Torrini, C., Shang, E., Shu, C., Mun, J.-Y., Gao, Q., Humala, N., Akman, H. O., Zhang, G., Westhoff, M.-A., Karpel-Massler, G., Bruce, J. N., Canoll, P., & Siegelin, M. D. (2024). OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma. JCI Insight. https://doi.org/10.1172/jci.insight.172565

Lee, I. Y., Hanft, S., Schulder, M., Judy, K. D., Wong, E. T., Elder, J. B., Evans, L. T., Zuccarello, M., Wu, J., Aulakh, S., Agarwal, V., Ramakrishna, R., Gill, B. J., Quiñones-Hinojosa, A., Brennan, C., Zacharia, B. E., Silva Correia, C. E., Diwanji, M., Pennock, G. K., … Boockvar, J. A. (2024). Autologous Cell Immunotherapy (IGV-001) with IGF-1R Antisense Oligonucleotide in Newly Diagnosed Glioblastoma Patients. Future Oncology, 20(10), 579–591. https://doi.org/10.2217/fon-2023-0702

Cao, Q., Hajosch, A., Kast, R. E., Loehmann, C., Hlavac, M., Fischer-Posovszky, P., Strobel, H., Westhoff, M.-A., Siegelin, M. D., Wirtz, C. R., Halatsch, M.-E., & Karpel-Massler, G. (2024). Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. British Journal of Cancer, 130(8), 1365–1376. https://doi.org/10.1038/s41416-024-02608-8

Jimenez, A. E., Chakravarti, S., Liu, J., Kazemi, F., Jackson, C., Gallia, G., Bettegowda, C., Weingart, J., Brem, H., & Mukherjee, D. (2024). The Hospital Frailty Risk Score Independently Predicts Postoperative Outcomes in Glioblastoma Patients. World Neurosurgery, 183, e747–e760. https://doi.org/10.1016/j.wneu.2024.01.021

Rahman, R., Trippa, L., Lee, E. Q., Arrillaga-Romany, I., Fell, G., Touat, M., McCluskey, C., Wiley, J., Gaffey, S., Drappatz, J., Welch, M. R., Galanis, E., Ahluwalia, M. S., Colman, H., Nabors, L. B., Hepel, J., Elinzano, H., Schiff, D., Chukwueke, U. N., … Wen, P. Y. (2023). Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization. Journal of Clinical Oncology, 41(36), 5524–5535. https://doi.org/10.1200/jco.23.00493

Kinslow, C. J., Siegelin, M. D., Iwamoto, F. M., Gallitto, M., Neugut, A. I., Yu, J. B., Cheng, S. K., & Wang, T. J. C. (2023). MGMT promoter methylation in 1p19q-intact gliomas. Journal of Neuro-Oncology, 166(1), 73–78. https://doi.org/10.1007/s11060-023-04515-z

Al-Dalahmah, O., Argenziano, M. G., Kannan, A., Mahajan, A., Furnari, J., Paryani, F., Boyett, D., Save, A., Humala, N., Khan, F., Li, J., Lu, H., Sun, Y., Tuddenham, J. F., Goldberg, A. R., Dovas, A., Banu, M. A., Sudhakar, T., Bush, E., … Canoll, P. (2023). Re-convolving the compositional landscape of primary and recurrent glioblastoma reveals prognostic and targetable tissue states. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-38186-1

Zhao, Q., Hu, J., Kong, L., Jiang, S., Tian, X., Wang, J., Hashizume, R., Jia, Z., Fowlkes, N. W., Yan, J., Xia, X., Yi, S. F., Dao, L. H., Masopust, D., Heimberger, A. B., & Li, S. (2023). FGL2-targeting T cells exhibit antitumor effects on glioblastoma and recruit tumor-specific brain-resident memory T cells. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-36430-2

Dmello, C., Zhao, J., Chen, L., Gould, A., Castro, B., Arrieta, V. A., Zhang, D. Y., Kim, K.-S., Kanojia, D., Zhang, P., Miska, J., Yeeravalli, R., Habashy, K., Saganty, R., Kang, S. J., Fares, J., Liu, C., Dunn, G., Bartom, E., … Sonabend, A. M. (2023). Checkpoint kinase 1/2 inhibition potentiates anti-tumoral immune response and sensitizes gliomas to immune checkpoint blockade. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-36878-2

Kinslow, C. J., Rae, A. I., Taparra, K., Kumar, P., Siegelin, M. D., Grinband, J., Gill, B. J. A., McKhann, G. M., Sisti, M. B., Bruce, J. N., Canoll, P. D., Iwamoto, F. M., Horowitz, D. P., Kachnic, L. A., Neugut, A. I., Yu, J. B., Cheng, S. K., & Wang, T. J. C. (2023). MGMT Promoter Methylation Predicts Overall Survival after Chemotherapy for 1p/19q-Codeleted Gliomas. Clinical Cancer Research, 29(21), 4399–4407. https://doi.org/10.1158/1078-0432.ccr-23-1295

Johnson, M., Bell, A., Lauing, K. L., Ladomersky, E., Zhai, L., Penco-Campillo, M., Shah, Y., Mauer, E., Xiu, J., Nicolaides, T., Drumm, M., McCortney, K., Elemento, O., Kim, M., Bommi, P., Low, J. T., Memon, R., Wu, J., Zhao, J., … Wainwright, D. A. (2023). Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence. Clinical Cancer Research, 29(23), 4973–4989. https://doi.org/10.1158/1078-0432.ccr-23-0834

De Martino, M., Daviaud, C., Minns, H. E., Lazarian, A., Wacker, A., Costa, A. P., Attarwala, N., Chen, Q., Choi, S.-W., Rabadàn, R., McIntire, L. B. J., Gartrell, R. D., Kelly, J. M., Laiakis, E. C., & Vanpouille-Box, C. (2023). Radiation therapy promotes unsaturated fatty acids to maintain survival of glioblastoma. Cancer Letters, 570, 216329. https://doi.org/10.1016/j.canlet.2023.216329

Zheng, C., Wei, Y., Zhang, Q., Sun, M., Wang, Y., Hou, J., Zhang, P., Lv, X., Su, D., Jiang, Y., Gumin, J., Sahni, N., Hu, B., Wang, W., Chen, X., McGrail, D. J., Zhang, C., Huang, S., Xu, H., … Chen, Y. (2023). Multiomics analyses reveal DARS1-AS1 /YBX1–controlled posttranscriptional circuits promoting glioblastoma tumorigenesis/radioresistance. Science Advances, 9(31). https://doi.org/10.1126/sciadv.adf3984

Ellingson, B. M., Wen, P. Y., Chang, S. M., van den Bent, M., Vogelbaum, M. A., Li, G., Li, S., Kim, J., Youssef, G., Wick, W., Lassman, A. B., Gilbert, M. R., de Groot, J. F., Weller, M., Galanis, E., & Cloughesy, T. F. (2023). Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro-Oncology, 25(6), 1017–1028. https://doi.org/10.1093/neuonc/noad002

Mair, M. J., Bartsch, R., Le Rhun, E., Berghoff, A. S., Brastianos, P. K., Cortes, J., Gan, H. K., Lin, N. U., Lassman, A. B., Wen, P. Y., Weller, M., van den Bent, M., & Preusser, M. (2023). Understanding the activity of antibody–drug conjugates in primary and secondary brain tumours. Nature Reviews Clinical Oncology, 20(6), 372–389. https://doi.org/10.1038/s41571-023-00756-z

Vize, C. J., Kim, S. K., Matthews, T., Macsai, M., Merrell, R., Hsu, S., Kundu, M. G., Yoon, J., Kennedy, E., Pai, M., Bain, E., Lassman, A. B., & Moazami, G. (2023). A Phase 3b Study for Management of Ocular Side Effects in Patients with Epidermal Growth Factor Receptor-Amplified Glioblastoma Receiving Depatuxizumab Mafodotin. Ophthalmic Research, 1030–1043. Portico. https://doi.org/10.1159/000531142

Shang, E., Nguyen, T. T. T., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. (2023). Targeting cellular respiration as a therapeutic strategy in glioblastoma. Oncotarget, 14(1), 419–425. https://doi.org/10.18632/oncotarget.28424

Gao, S., Jin, L., Moliterno, J., Corbin, Z. A., Bindra, R. S., Contessa, J. N., Yu, J. B., & Park, H. S. (2023). Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma. Journal of Neurosurgery, 138(3), 610–620. https://doi.org/10.3171/2022.5.jns212761

Alkazemi, M., Lo, Y. T., Hussein, H., Mammi, M., Saleh, S., Araujo-Lama, L., Mommsen, S., Pisano, A., Lamba, N., Bunevicius, A., & Mekary, R. A. (2023). Laser Interstitial Thermal Therapy for the Treatment of Primary and Metastatic Brain Tumors: A Systematic Review and Meta-Analysis. World Neurosurgery, 171, e654–e671. https://doi.org/10.1016/j.wneu.2022.12.079

Lassman, A. B., Pugh, S. L., Wang, T. J. C., Aldape, K., Gan, H. K., Preusser, M., Vogelbaum, M. A., Sulman, E. P., Won, M., Zhang, P., Moazami, G., Macsai, M. S., Gilbert, M. R., Bain, E. E., Blot, V., Ansell, P. J., Samanta, S., Kundu, M. G., Armstrong, T. S., … Mehta, M. P. (2022). Depatuxizumab mafodotin in EGFR-amplified newly diagnosed glioblastoma: A phase III randomized clinical trial. Neuro-Oncology, 25(2), 339–350. https://doi.org/10.1093/neuonc/noac173

Migliozzi, S., Oh, Y. T., Hasanain, M., Garofano, L., D’Angelo, F., Najac, R. D., Picca, A., Bielle, F., Di Stefano, A. L., Lerond, J., Sarkaria, J. N., Ceccarelli, M., Sanson, M., Lasorella, A., & Iavarone, A. (2023). Integrative multi-omics networks identify PKCδ and DNA-PK as master kinases of glioblastoma subtypes and guide targeted cancer therapy. Nature Cancer, 4(2), 181–202. https://doi.org/10.1038/s43018-022-00510-x

Liau, L. M., Ashkan, K., Brem, S., Campian, J. L., Trusheim, J. E., Iwamoto, F. M., Tran, D. D., Ansstas, G., Cobbs, C. S., Heth, J. A., Salacz, M. E., D’Andre, S., Aiken, R. D., Moshel, Y. A., Nam, J. Y., Pillainayagam, C. P., Wagner, S. A., Walter, K. A., Chaudhary, R., … Bosch, M. L. (2023). Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma. JAMA Oncology, 9(1), 112. https://doi.org/10.1001/jamaoncol.2022.5370

Gallitto, M., Savacool, M., Lee, A., Wang, T. J. C., & Sisti, M. B. (2022). Feasibility of fractionated gamma knife radiosurgery in the management of newly diagnosed Glioblastoma. BMC Cancer, 22(1). https://doi.org/10.1186/s12885-022-10162-w

Spinazzi, E. F., Argenziano, M. G., Upadhyayula, P. S., Banu, M. A., Neira, J. A., Higgins, D. M. O., Wu, P. B., Pereira, B., Mahajan, A., Humala, N., Al-Dalahmah, O., Zhao, W., Save, A. V., Gill, B. J. A., Boyett, D. M., Marie, T., Furnari, J. L., Sudhakar, T. D., Stopka, S. A., … Bruce, J. N. (2022). Chronic convection-enhanced delivery of topotecan for patients with recurrent glioblastoma: a first-in-patient, single-centre, single-arm, phase 1b trial. The Lancet Oncology, 23(11), 1409–1418. https://doi.org/10.1016/s1470-2045(22)00599-x

Dileep Kumar, J. S., Molotkov, A., Carberry, P., Chaly, T., Neelamegam, R., & Mintz, A. (2022). Radiosynthesis and evaluation of [11C]AG-488, a dual anti-angiogenetic and anti-tubulin PET ligand. Bioorganic & Medicinal Chemistry Letters, 74, 128941. https://doi.org/10.1016/j.bmcl.2022.128941

Nguyen, T. T. T., Shang, E., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. (2022). Therapeutic Drug-Induced Metabolic Reprogramming in Glioblastoma. Cells, 11(19), 2956. https://doi.org/10.3390/cells11192956

Venkataramani, V., Yang, Y., Schubert, M. C., Reyhan, E., Tetzlaff, S. K., Wißmann, N., Botz, M., Soyka, S. J., Beretta, C. A., Pramatarov, R. L., Fankhauser, L., Garofano, L., Freudenberg, A., Wagner, J., Tanev, D. I., Ratliff, M., Xie, R., Kessler, T., Hoffmann, D. C., … Winkler, F. (2022). Glioblastoma hijacks neuronal mechanisms for brain invasion. Cell, 185(16), 2899-2917.e31. https://doi.org/10.1016/j.cell.2022.06.054

Torrini, C., Nguyen, T. T. T., Shu, C., Mela, A., Humala, N., Mahajan, A., Seeley, E. H., Zhang, G., Westhoff, M.-A., Karpel-Massler, G., Bruce, J. N., Canoll, P., & Siegelin, M. D. (2022). Lactate is an epigenetic metabolite that drives survival in model systems of glioblastoma. Molecular Cell, 82(16), 3061-3076.e6. https://doi.org/10.1016/j.molcel.2022.06.030

Kenchappa, R. S., Dovas, A., Argenziano, M. G., Meyer, C. T., Stopfer, L. E., Banu, M. A., Pereira, B., Griffith, J., Mohammad, A., Talele, S., Haddock, A., Zarco, N., Elmquist, W., White, F., Quaranta, V., Sims, P., Canoll, P., & Rosenfeld, S. S. (2022). Activation of STAT3 through combined SRC and EGFR signaling drives resistance to a mitotic kinesin inhibitor in glioblastoma. Cell Reports, 39(12), 110991. https://doi.org/10.1016/j.celrep.2022.110991

Nguyen, T. T. T., Shang, E., Schiffgens, S., Torrini, C., Shu, C., Akman, H. O., Prabhu, V. V., Allen, J. E., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. (2022). Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma. Clinical Cancer Research, 28(9), 1881–1895. https://doi.org/10.1158/1078-0432.ccr-21-2857

Yuen, C. A., Barbaro, M., & Haggiagi, A. (2022). Newly Diagnosed Glioblastoma in Elderly Patients. Current Oncology Reports, 24(3), 325–334. https://doi.org/10.1007/s11912-022-01201-7

Arrieta, V. A., Chen, A. X., Kane, J. R., Kang, S. J., Kassab, C., Dmello, C., Zhao, J., Burdett, K. B., Upadhyayula, P. S., Lee-Chang, C., Shilati, J., Jaishankar, D., Chen, L., Gould, A., Zhang, D., Yuan, J., Zhao, W., Ling, X., Burks, J. K., … Sonabend, A. M. (2021). ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nature Cancer, 2(12), 1372–1386. https://doi.org/10.1038/s43018-021-00260-2

Sen, A., Prager, B. C., Zhong, C., Park, D., Zhu, Z., Gimple, R. C., Wu, Q., Bernatchez, J. A., Beck, S., Clark, A. E., Siqueira-Neto, J. L., Rich, J. N., & McVicker, G. (2021). Leveraging Allele-Specific Expression for Therapeutic Response Gene Discovery in Glioblastoma. Cancer Research, 82(3), 377–390. https://doi.org/10.1158/0008-5472.can-21-0810

Persico, M., Abbruzzese, C., Matteoni, S., Matarrese, P., Campana, A. M., Villani, V., Pace, A., & Paggi, M. G. (2022). Tackling the Behavior of Cancer Cells: Molecular Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma. Cells, 11(2), 263. https://doi.org/10.3390/cells11020263

Nguyen, T. T. T., Shang, E., Westhoff, M.-A., Karpel-Massler, G., & Siegelin, M. D. (2022). Methodological Approaches for Assessing Metabolomic Changes in Glioblastomas. Autophagy and Cancer, 305–328. https://doi.org/10.1007/978-1-0716-2071-7_19

Lee, M., Woo, J., Kim, D.-H., Yang, Y.-M., Lee, E. Y., Kim, J.-H., Kang, S.-G., Shim, J.-K., & Park, J.-Y. (2021). A novel paper MAP method for rapid high resolution histological analysis. Scientific Reports, 11(1). https://doi.org/10.1038/s41598-021-02632-1